Alendronate Tablet
Product Images NDC 10135-719

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 10135-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Alendronate-35mg-3x4 (Alendronalte 35mg 3x4)

Alendronate-35mg-3x4 (Alendronalte 35mg 3x4)
FDA Label Image

Alendronate-35mg-4 (Alendronate 35mg 4)

Alendronate-35mg-4 (Alendronate 35mg 4)
FDA Label Image

Alendronate-70mg-2x10 (Alendronate 70mg 2x10)

Alendronate-70mg-2x10 (Alendronate 70mg 2x10)
FDA Label Image

Alendronate-70mg-3x4 (Alendronate 70mg 3x4)

Alendronate-70mg-3x4 (Alendronate 70mg 3x4)
FDA Label Image

Alendronate-70mg-4 (Alendronate 70mg 4)

Alendronate-70mg-4 (Alendronate 70mg 4)
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
This appears to be a table or graph showing data for two studies comparing the effects of Alendronate Sodium 10 mg (a medication used to treat or prevent osteoporosis) versus a placebo on bone mineral density (BMD) over a period of 36 months. The data is presented as mean percent change from baseline, and there are separate results displayed for a US study and a multinational study. The table/graph also shows the time points at which the BMD measurements were taken (0, 12, 24, and 36 months).*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
The text provides a figure numbered as 5, which indicates an increase in BMD (Bone Mineral Density) in glucocorticoid-treated patients. The text further mentions the dosage of Alendronates administered per day for one year as the treatment. The increase in BMD is represented as a mean of 9% relative to placebo + SE. The figure possibly indicates the increase in BMD at the Lumbar Spine, Femoral Neck, and Trochanter.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
This is a graph showing the effect of Alendronate 40 mg/day versus placebo or Etidronate 400 mg/day on Serum Alkaline Phosphatase in Stu Paget's Disease of Bone over time in months.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.